Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.62)
# 689
Out of 4,826 analysts
100
Total ratings
56.14%
Success rate
3.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $62.06 | +45.02% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $500.19 | -4.04% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $50.06 | +9.87% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $102.81 | -22.19% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $6.81 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $603.58 | +68.16% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $279.80 | +44.75% | 2 | Oct 22, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Neutral | $220 | $273.55 | -19.58% | 23 | Oct 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Overweight | $10 | $8.26 | +21.07% | 5 | Sep 16, 2024 | |
| MNKD MannKind | Reiterates: Overweight | $6.5 | $4.98 | +30.65% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $37.62 | +91.39% | 1 | Apr 13, 2023 |
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $62.06
Upside: +45.02%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $500.19
Upside: -4.04%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $50.06
Upside: +9.87%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $102.81
Upside: -22.19%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $6.81
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $603.58
Upside: +68.16%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $279.80
Upside: +44.75%
Alnylam Pharmaceuticals
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $273.55
Upside: -19.58%
Aurinia Pharmaceuticals
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $8.26
Upside: +21.07%
MannKind
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $4.98
Upside: +30.65%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $37.62
Upside: +91.39%